![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MORPHOSYS STARTS MULTIPLE ANTIBODY PROGRAMS WITH SCHERING AG
MORPHOSYS STARTS MULTIPLE ANTIBODY PROGRAMS WITH SCHERING AG
October 11, 2005
MorphoSys AG (Frankfurt Stock Exchange:MOR) (Prime Standard Segment:TecDAX) announced today the start of a further three therapeutic antibody programs within the scope of its collaboration with Schering AG, Germany (FSE:SCH) (NYSE:SHR). Schering has selected three new target molecules, against which MorphoSys will generate antibodies using its proprietary HuCAL GOLD(r) technology. Additionally, MorphoSys has granted Schering eight exclusive licenses for in vivo diagnostic applications.
PrimeZone (http://www.primezone.com/newsroom/news.html?d=87559)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct